Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leveraging tumor dynamics to discover mutations influencing progression and treatment response for precision oncology.

Genome medicine - 17 Jun 2026

Petter Ella, LoPiccolo Jaclyn, Groha Stefan, Border Richard, Pasaniuc Bogdan, Kehl Kenneth L, Zaitlen Noah, Gusev Alexander

Abstract excerpt

BACKGROUND: Current research in precision oncology focuses on progression-free survival (PFS) and overall survival (OS) as the key outcomes. This stands in stark contrast to the primary outcomes guiding cancer treatment in the clinic- dynamic changes in tumor size in response to treatment. While PFS and OS are meaningful, highly interpretable and easily collected, we hypothesize that revealing associations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Lung Neoplasms

Share to Mutation

Share to Precision Medicine

Share to Progression-Free Survival

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42310804
DOI: 10.1186/s13073-026-01695-x
PMCID: PMC13523221

Genes

EGFR
GATA3
MYBL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leveraging tumor dynamics to discover mutations influencing progression and treatment response for precision oncology.PMID 42310804Read ↗

Natural history model predicts benefits associated with screening for lung cancer by detecting circulating tumor DNASemantic proximity Read ↗

A Novel Cell-Free DNA Fragmentomics Assay and Its Application for Monitoring Disease Progression in Real-Time for Stage IV Cancer PatientsSemantic proximity Read ↗

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx StudySemantic proximity Read ↗

Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity Read ↗

PICDGI: A framework for predicting cancer driver genes through dynamic gene-gene interaction modeling of single-cell data.Semantic proximity Read ↗

Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseSemantic proximity Read ↗

Predicting tumour evolution and drug resistance from heterogenous longitudinal cancer dataSemantic proximity Read ↗

Modeling metastatic progression from cross-sectional cancer genomics data.Semantic proximity Read ↗

3D, multi-omic imaging reveals molecular biomarkers of the pre-metastatic niche in lung cancerSemantic proximity Read ↗

The biology underlying molecular imaging in oncology: from genome to anatome and back again.Semantic proximity Read ↗

A Scalable Framework for Pan-Cancer Tumor Evolution Analysis Enables Transfer of Progression Mechanisms Across Tumor EntitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.